Pear Therapeutics, Inc.
PEARDelisted May 2, 2023- Industry
- Services-Health Services
- SEC CIK
- 0001835567
Pear Therapeutics, Inc. was delisted on May 2, 2023; its insiders filed their last Form 4 on Apr 12, 2023; 53 institutions reported holding it in 13F filings for Q1 2023, worth $20.7M in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 2:35 PM ET
Revenue flow, FY2022
Where the revenue went in FY2022, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2022: $75.5M (594.7% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2022 | FY2021 |
|---|---|---|
| Period end | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K |
| Reported | Mar 17, 2023 | Jan 11, 2022 |
| Revenue | $12.7M | $4.21M |
| Cost of revenue | $8.18M | $5.23M |
| Research and development | $48.3M | $37.0M |
| Selling, general and administrative | $79.6M | $67.6M |
| Operating income | -$123.3M | -$105.7M |
| Income tax | $0 | $0 |
| Net income | -$75.5M | -$65.1M |
| EPS, basic | $-0.54 | $-0.57 |
| EPS, diluted | $-0.54 | $-0.57 |
| Weighted shares, basic | 138.7M | 113.3M |
| Weighted shares, diluted | 138.7M | 113.3M |
| Margins and growth | ||
| Operating margin | -971.7% | -2511.5% |
| Net margin | -594.7% | -1548.1% |
| Revenue growth, year over year | +201.7% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2022 | FY2021 |
|---|---|---|
| Period end | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K |
| Reported | Mar 17, 2023 | Jan 11, 2022 |
| Cash and equivalents | $48.3M | $169.6M |
| Short-term investments | $11.0M | $5.00M |
| Accounts receivable | $6.94M | $1.79M |
| Total current assets | $73.0M | $185.2M |
| Property, plant and equipment | $6.08M | $6.25M |
| Total assets | $95.1M | $197.2M |
| Accounts payable | $3.26M | $1.81M |
| Short-term debt | $27.4M | $27.0M |
| Total current liabilities | $49.4M | $47.2M |
| Long-term debt | $0 | $0 |
| Total liabilities | $64.5M | $106.7M |
| Shareholders' equity | $30.6M | $90.4M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2022 | FY2021 |
|---|---|---|
| Period end | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K |
| Reported | Mar 17, 2023 | Jan 11, 2022 |
| Operating cash flow | -$113.9M | -$109.0M |
| Capital expenditures | $3.47M | $3.28M |
| Free cash flow | -$117.4M | -$112.3M |
| Stock-based compensation | $13.5M | $3.81M |
| Investing cash flow | -$9.46M | $2.88M |
| Financing cash flow | $2.15M | $164.1M |
| Net change in cash | -$121.2M | $57.9M |
| Ratio | ||
| Stock-based compensation, % of revenue | 106.6% | 90.5% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.